» Articles » PMID: 1730684

Androgen Receptor Phosphorylation, Turnover, Nuclear Transport, and Transcriptional Activation. Specificity for Steroids and Antihormones

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1992 Jan 15
PMID 1730684
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear transport, phosphorylation, ligand binding, and degradation rate of the recombinant androgen receptor (AR) were analyzed in transfected COS cells in the presence of various steroids and antiandrogens. Transcriptional activation was assessed in CV1 cells by cotransfection with an androgen-responsive chloramphenicol acetyltransferase (CAT) reporter vector. Hormone binding specificity of recombinant AR was essentially identical to endogenous AR. AR localized in the nucleus in the presence of methyltrienolone (R1881, a synthetic androgen), dihydrotestosterone, testosterone, hydroxyflutamide, cyproterone acetate, estradiol, progesterone, and RU486. In the absence of hormone or with the antiandrogen, flutamide, AR remained largely in the cytoplasm with a perinuclear distribution. AR was degraded rapidly (t1/2 = 1 h) except in the presence of androgen (t1/2 = 6 h) which accounted for an apparent 2-4-fold androgen-induced increase in AR phosphorylation, indicating that AR phosphorylation was not enhanced by androgen. CAT activity was stimulated by R1881, dihydrotestosterone, testosterone, cyproterone acetate, estradiol, progesterone, and RU486 in a dose-dependent manner. The antiandrogens, flutamide and hydroxyflutamide, lacked agonist activity and inhibited R1881-induced activation of CAT and androgen stabilization of AR. Steroids and antiandrogens with moderate to low affinity for AR promoted both nuclear transport and transcriptional activation but only at high hormone concentrations. Hydroxyflutamide acted as a true antiandrogen since it lacked agonist activity and was an inhibitor of androgen-induced transcriptional activation.

Citing Articles

A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.

Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S Proc Natl Acad Sci U S A. 2024; 121(40):e2406837121.

PMID: 39312663 PMC: 11459127. DOI: 10.1073/pnas.2406837121.


Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats.

Lee S, Lee S, Song J Nutrients. 2024; 16(8).

PMID: 38674879 PMC: 11054461. DOI: 10.3390/nu16081189.


A phenotypically robust model of spinal and bulbar muscular atrophy in Drosophila.

Richardson K, Sengupta M, Sujkowski A, Libohova K, Harris A, Wessells R J Neurosci Res. 2024; 102(1):e25278.

PMID: 38284836 PMC: 11237963. DOI: 10.1002/jnr.25278.


Therapeutic Potential of Bipolar Androgen Therapy for Castration-Resistant Prostate Cancer: In Vitro and In Vivo Studies.

Yu J, Lim J, Song W Biomedicines. 2024; 12(1).

PMID: 38255286 PMC: 10813541. DOI: 10.3390/biomedicines12010181.


The role of ubiquitination in spinal and bulbar muscular atrophy.

Sengupta M, Pluciennik A, Merry D Front Mol Neurosci. 2022; 15:1020143.

PMID: 36277484 PMC: 9583669. DOI: 10.3389/fnmol.2022.1020143.